Evidence map›Paper›PMID 28003422›Full record

ArticleJournal of clinical microbiology2017

Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria.

Pieter-Jan Ceyssens, Karine Soetaert, Markus Timke, An Van den Bossche, Katrin Sparbier, Koen De Cremer, Markus Kostrzewa, Marijke Hendrickx, Vanessa Mathys

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in Journal of clinical microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. mBio · 2024
    Article
  6. Diagnostic efficacy of an optimized nucleotide MALDI-TOF-MS assay for anti-tuberculosis drug resistance detection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Microorganisms · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Pieter-Jan CeyssensNational Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Karine SoetaertNational Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Markus TimkeBruker Daltonik GmbH, Bremen, Germany.
An Van den BosscheNational Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Katrin SparbierBruker Daltonik GmbH, Bremen, Germany.
Koen De CremerHealth and Environment, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Markus KostrzewaBruker Daltonik GmbH, Bremen, Germany.
Marijke HendrickxMycology & Aerobiology, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Vanessa MathysNational Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium vanessa.mathys@wiv-isp.be.
Institut Scientifique de Santé Publique · BEBruker (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Species identification and drug susceptibility testing (DST) of mycobacteria are important yet complex processes traditionally reserved for reference laboratories. Recent technical improvements in matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has started to facilitate routine mycobacterial identifications in clinical laboratories. In this paper, we investigate the possibility of performing phenotypic MALDI-based DST in mycobacteriology using the recently described MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA). We randomly selected 72 clinical Mycobacterium tuberculosis and nontuberculous mycobacterial (NTM) strains, subjected them to MBT-ASTRA methodology, and compared its results to current gold-standard methods. Drug susceptibility was tested for rifampin, isoniazid, linezolid, and ethambutol (M. tuberculosis, n = 39), and clarithromycin and rifabutin (NTM, n = 33). Combined species identification was performed using the Biotyper Mycobacteria Library 4.0. Mycobacterium-specific MBT-ASTRA parameters were derived (calculation window, m/z 5,000 to 13,000, area under the curve [AUC] of >0.015, relative growth [RG] of <0.5; see the text for details). Using these settings, MBT-ASTRA analyses returned 175/177 M. tuberculosis and 65/66 NTM drug resistance profiles which corresponded to standard testing results. Turnaround times were not significantly different in M. tuberculosis testing, but the MBT-ASTRA method delivered on average a week faster than routine DST in NTM. Databases searches returned 90.4% correct species-level identifications, which increased to 98.6% when score thresholds were lowered to 1.65. In conclusion, the MBT-ASTRA technology holds promise to facilitate and fasten mycobacterial DST and to combine it directly with high-confidence species-level identifications. Given the ease of interpretation, its application in NTM typing might be the first in finding its way to current diagnostic workflows. However, further validations and automation are required before routine implementation can be envisioned.

Indexed as

Antitubercular AgentsBacteriological TechniquesHumansMycobacterium tuberculosisNontuberculous MycobacteriaSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAntitubercular Agentsdrug susceptibility testingMALDI-TOFMBT-ASTRAmycobacteria

Identifiers

PMID28003422
PMCPMC5277533
OpenAlexW2567661625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.